Seerlinq
Seerlinq is a Slovak medical technology company providing AI-powered, non-invasive remote monitoring of cardiac filling pressures for heart failure patients via PPG signal analysis. Its certified Class II(b) HeartCore device is fully reimbursed by public health insurers in Slovakia and Germany.
- Company typePrivate
- Founded2022
- HeadquartersTrnava
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Seerlinq does
Seerlinq s.r.o. is a Slovak medical technology company that develops AI-based, non-invasive solutions for remote hemodynamic monitoring of heart failure patients. Its core product, Seerlinq HeartCore, is a certified Class II(b) medical device under EU MDR 2017/745 that uses photoplethysmography (PPG) signal analysis — captured via a standard pulse oximeter — to estimate left ventricular filling pressure (LVFP) and the Diastolic Reserve Index (DRI), enabling early detection of heart failure deterioration without invasive implants. The integrated system pairs the HeartCore algorithm with a patient-facing mobile application, a specialist-staffed telemonitoring service, and cloud infrastructure hosted on AWS (EU data centers). Patients measure themselves every other day for approximately four minutes; the system analyzes PPG signals, generates alerts on deterioration, and escalates to physicians when clinical intervention is needed. Validation studies demonstrate robust discrimination against invasive PCWP reference standards and a 12-month pilot of 30 high-risk patients yielded zero HF hospitalizations versus an expected ~50% baseline.
Seerlinq monetizes primarily through health insurance reimbursement: all three Slovak public insurers (VšZP, Dôvera, Union) and German public health insurance cover the service for heart failure patients with no co-pay, plus a secondary fee-for-service stream for non-HF cardiovascular indications. The company runs a physician-referral go-to-market motion with field sales teams in Slovakia and Germany, supplemented by direct-to-patient enrollment via its multilingual website. To date, the program serves 200+ patients across Slovakia with 50+ partner physicians and has active pilot projects in seven countries, including strategic partnerships with Sheba Medical Center (Israel) and Royal Brompton & Harefield Hospital (UK).
Founded by cardiologist Dr. Allan Böhm (ESC President 2020), cardiac surgeon Dr. Branislav Bezák, and computer scientist Dr. Nikola Jajcay, Seerlinq operates from Trnava, Slovak Republic, with 1–10 employees and approximately €900K in cumulative funding. The company is positioned at the intersection of AI, non-invasive diagnostics, and reimbursed digital therapeutics, with ongoing international expansion across Europe and a regulatory foundation (ISO 13485 / MDSAP readiness) built for future US and global market entry.
Seerlinq firmographics
Firmographics- Name
- Seerlinq
- Legal name
- Seerlinq s.r.o.
- Website
- https://seerlinq.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Seerlinq is a Slovak medical technology company providing AI-powered, non-invasive remote monitoring of cardiac filling pressures for heart failure patients via PPG signal analysis. Its certified Class II(b) HeartCore device is fully reimbursed by public health insurers in Slovakia and Germany.
- Ownership category
- akta.pro rank
Seerlinq industry classification
Industry- Product category
- Remote Cardiac Monitoring
- NAICS
- Home Health Care Services (62161)
- SIC
- Services-Home Health Care Services (8082)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Home Cardiac Care & Remote Patient Monitoring (Skilled Oversight) (HLADAFAJ)
Keywords
Where Seerlinq is headquartered
LocationHeadquarters
- HQ city
- Trnava
Offices1 record
Markets served
Seerlinq business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Health Insurance Reimbursement (Slovakia): Seerlinq's primary revenue stream comes from reimbursement by all Slovak health insurance companies for heart failure patients. The service is fully covered, with no co-pay required from patients. This reimbursement model covers the device, app, monitoring, and clinical oversight.
- Health Insurance Reimbursement (Germany): The company is expanding into the German market with reimbursement through the German public health insurance system. The website states the service is fully reimbursed by public health insurance in Slovakia and Germany.
- Fee-for-Service for Non-Heart Failure Cardiovascular Patients: For patients with other cardiovascular diseases (beyond heart failure), the Seerlinq service is provided on a fee basis, negotiated through consultation with the physician. This represents a secondary revenue stream for patients not covered under the heart failure indication.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Heart Failure Patients — Fully Covered |
| Other | Pay-as-you-go | Other Cardiovascular Disease Patients — Fee-Based |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels8 records
Seerlinq product offering
Product offeringCore offering
Seerlinq provides a non-invasive remote cardiac monitoring service for heart failure patients based on its proprietary HeartCore algorithm, which analyzes photoplethysmography (PPG) signals from a standard pulse oximeter to estimate left ventricular filling pressure (LVFP) and the Diastolic Reserve Index (DRI). The service bundles a certified Class II(b) medical device, a patient-facing mobile application, AI-driven analytics, and continuous oversight by cardiology specialists who coordinate with the patient's cardiologist to detect early deterioration and prevent hospitalizations. The offering is delivered as a fully reimbursed telemonitoring service in Slovakia and Germany.
Product overview
Seerlinq offers an integrated medical device system for heart failure patients, combining the Seerlinq HeartCore hardware device with the Seerlinq HF mobile application and a telemedicine monitoring service. The core product, Seerlinq HeartCore, is a certified Class II(b) medical device that uses photoplethysmography (PPG) signal analysis to non-invasively monitor cardiac filling pressures. The mobile app enables patients to perform regular measurements, while the platform's AI-powered HeartCore algorithm analyzes the data to detect early signs of deterioration. A team of cardiology specialists provides continuous remote monitoring and coordinates timely interventions with the patient's cardiologist to prevent hospitalizations.
Differentiator
Problem solved
Functional benefit
Brands
- Seerlinq HeartCore: A certified Class II(b) medical device under EU MDR 2017/745 that uses photoplethysmography (PPG) analysis for non-invasive remote monitoring of cardiac filling pressures in heart failure patients.
Products and services
- Seerlinq HeartCore A certified Class II(b) medical device under EU MDR 2017/745 that uses proprietary photoplethysmography (PPG) signal analysis to non-invasively estimate left ventricular filling pressure (LVFP) and the Diastolic Reserve Index (DRI), enabling early detection of heart failure deterioration in the home environment.
- Seerlinq HF Mobile Application Patient-facing mobile application that guides patients through the measurement protocol (2 minutes standing and 2 minutes lying down every other day), receives PPG and blood pressure data, transmits readings to the Seerlinq platform, and enables remote cardiology specialist review with real-time alerts when deterioration is detected.
- Seerlinq Telemedicine Service End-to-end remote cardiac monitoring service for heart failure patients combining the Seerlinq HeartCore device, the mobile application, AI-based signal analysis, and continuous oversight by cardiology specialists who coordinate with the patient's cardiologist to detect deterioration early and prevent hospitalizations. Fully reimbursed by health insurance in Slovakia and Germany for the heart failure indication.
Quantifiable outcome
- 30 high-risk heart failure patients monitored for 12 consecutive months with zero hospitalizations due to heart failure deterioration (vs. expected 50% hospitalization rate)
- +4 more outcomes
Companies that use Seerlinq
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles4 records
Seerlinq technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Seerlinq partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Sheba Medical Center (Tel Aviv, Israel)coreSheba Medical Center, one of the world's leading hospitals, is a pilot project partner for Seerlinq. The collaboration involves testing and validating the Seerlinq non-invasive hemodynamic monitoring technology in Sheba's clinical environment, contributing to international clinical evidence generation and market validation.
- Royal Brompton & Harefield Hospital (London, UK)coreHarefield Hospital, a globally renowned cardiac care center, is a pilot project partner for Seerlinq. The partnership enables clinical validation of the technology in a leading UK cardiac setting and provides international credibility for the technology's clinical efficacy.
- All Slovak Health Insurance CompaniescoreSeerlinq has reimbursement agreements with all three Slovak health insurance companies — Všeobecná zdravotná poisťovňa (VšZP), Dôvera, and Union. This means every heart failure patient in Slovakia has their Seerlinq telemonitoring fully covered, eliminating patient co-pay and enabling mass market access.
- Amazon Web Services (AWS)coreAWS serves as Seerlinq's main cloud infrastructure provider, hosting data in European Union data centers. AWS acts as a data processor under GDPR, processing personal and health data only on Seerlinq's documented instructions and under strict security and confidentiality obligations.
- Premedix Academy / Premedix CliniccorePremedix Academy is the biomedical organization founded by Dr. Allan Böhm in 2015 where the Seerlinq concept originated. Premedix Clinic is the precision medicine clinic in Slovakia that was established as a result of Böhm's work with the ESC Digital Medicine Committee. Both organizations serve as foundational partners in the Seerlinq ecosystem, contributing clinical expertise and research infrastructure.
- Slovak Investment and Trade Development Agency (SARIO)minorSARIO organized the Slovak pavilion at MEDICA in Düsseldorf, enabling Seerlinq to present Slovak medical technology at one of the world's largest medical trade fairs. This government trade agency provides international exposure and networking opportunities for Slovak medtech companies.
- Deutsche Gesellschaft für Telemedizin e.V. (DGTelemed)minorSeerlinq engaged with the German Telemedicine Society (DGTelemed) at MEDICA, building relationships within the German digital health community as part of its market entry strategy for Germany.
- SOSA (New York)minorSeerlinq participated in the SOSA accelerator program in New York, an intensive program that provides a bridge between Slovak innovation and the US medtech ecosystem. Stefan Karolcik (Head of Regulatory & Product) represented Seerlinq in the 8-day program, gaining exposure to the US market and potential US partners.
Scale indicators10 records
Recent moves8 records
Expansion highlights7 records
Seerlinq competitors and assessment
Company assessmentDirect peers
- CardioMEMS (Abbott): Abbott's CardioMEMS HF System is an implantable hemodynamic monitor that measures pulmonary artery pressure - the established clinical alternative for heart failure decompensation detection. Direct competitor to Seerlinq's non-invasive LVFP approach, though Seerlinq's value proposition is precisely to avoid the surgical implant and high cost that limit CardioMEMS adoption.
- Eko Health: Eko builds AI-enabled digital stethoscopes and cardiac monitoring tools used by cardiologists and primary care. Comparable as a digital cardiac diagnostics platform using AI on physiological signals, with overlapping physician customer base and similar point-of-care workflow integration ambitions.
- AliveCor (KardiaMobile): AliveCor produces FDA-cleared personal ECG devices (KardiaMobile) and an AI-based arrhythmia detection platform sold to patients and clinicians. Comparable as a consumer-friendly cardiac signal-monitoring device with AI analysis and remote physician review, with overlapping heart-failure and arrhythmia use cases.
- iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch uses AI to detect arrhythmias from continuous ECG data, reimbursed by CMS and major US payers. Comparable as an AI-enabled, patch/wearable-based cardiac monitoring service with a similar physician-report workflow and payer-reimbursement model.
Emerging players
- Vectorious Medical Technologies: Israel-based developer of the V-LAP system, a left atrial pressure sensor for heart failure monitoring. Comparable in focus on direct LV filling-pressure measurement for HF, but invasive/implantable, and like Seerlinq it has been piloted with leading cardiology centers and is pursuing reimbursement in Europe.
- Bodyport: Bodyport builds a cardiac scale that measures hemodynamic signals (fluid status, cardiac output) for at-home heart failure monitoring. Comparable in non-invasive, in-home hemodynamic monitoring for HF, addressing the same patient population with a different sensor form factor but similar clinical and reimbursement thesis.
Broad incumbents
- Biofourmis: Biofourmis offers an enterprise RPM platform with AI-driven analytics across multiple chronic conditions, including heart failure. Comparable as a remote-monitoring and predictive-analytics platform, but operates across a broader condition set rather than specializing in HF hemodynamic monitoring.
- Huma (formerly Medopad): Huma provides a digital health platform for remote patient monitoring, decentralized trials, and predictive care, with reimbursement partnerships across multiple European health systems. Comparable in using AI to detect deterioration and the European public-payer reimbursement model, but serves a much broader therapeutic area than Seerlinq.
- Preventice Solutions (Boston Scientific): Preventice (acquired by Boston Scientific) provides remote cardiac monitoring services including mobile cardiac telemetry and event monitoring. Comparable as a reimbursed, physician-prescribed cardiac RPM service with a similar patient-onboarding and physician-report workflow.
- Vivify Health (Optum): Vivify Health (now part of Optum) provides an enterprise RPM platform for chronic care management, including heart failure, with reimbursement-based billing to US payers. Comparable as a connected-care RPM platform reimbursed by health plans, with overlapping patient-onboarding and remote-monitoring operational model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Seerlinq social profiles
Digital presenceSeerlinq compliance and trust
Trust signalCompliance2 records
Seerlinq financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seerlinq leadership team
Management profileNumber of profiles
Profiles7 records
Seerlinq funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seerlinq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seerlinq
What does Seerlinq do?
Seerlinq provides a non-invasive remote cardiac monitoring service for heart failure patients based on its proprietary HeartCore algorithm, which analyzes photoplethysmography (PPG) signals from a standard pulse oximeter to estimate left ventricular filling pressure (LVFP) and the Diastolic Reserve Index (DRI). The service bundles a certified Class II(b) medical device, a patient-facing mobile application, AI-driven analytics, and continuous oversight by cardiology specialists who coordinate with the patient's cardiologist to detect early deterioration and prevent hospitalizations. The offering is delivered as a fully reimbursed telemonitoring service in Slovakia and Germany.
Is Seerlinq a public or private company?
Seerlinq is a private company. It is classified as venture growth investor backed and is currently operating.
When was Seerlinq founded?
Seerlinq was founded in 2022. It employs 11 to 50 people.
Where is Seerlinq based?
Seerlinq is headquartered in Trnava.
How does Seerlinq make money?
Three revenue lines are on record. Health Insurance Reimbursement (Slovakia) is the primary driver. The others are health Insurance Reimbursement (Germany) and fee-for-Service for Non-Heart Failure Cardiovascular Patients.
Who are Seerlinq's main competitors?
Direct peers on record are CardioMEMS (Abbott), Eko Health, AliveCor (KardiaMobile) and iRhythm Technologies. Emerging players are Vectorious Medical Technologies and Bodyport. Broad incumbents are Biofourmis, Huma (formerly Medopad), Preventice Solutions (Boston Scientific) and Vivify Health (Optum).
Does Seerlinq have an API?
No public API is recorded for Seerlinq.
What industry is Seerlinq in?
Seerlinq's product category is Remote Cardiac Monitoring. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 62161 and its SIC code is 8082.